Nanoparticles for preparing regulatory b cells
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Assistance Publique-Hopitaux de Paris, Universite De Paris, Universite Paris 13, Centre National de la Recherche Scientifique (CNRS)
InventorsChloé DUBREIL, Laurence MOTTE, Peter VAN ENDERT
Life of this patent
Estimating the term…
Abstract
The present invention relates to nanoparticles, kits, methods and compositions which are suitable for increasing the number of B regulatory (Breg) cells in a population of B cells; for producing Interleukin-10 (IL-10) or TGF-β. The inventors have shown that biocompatible nanoparticles comprising an antigen may be used for inducing B regulatory (Breg) cells. This production, either ex vivo, or in vivo, or in vitro, was associated to temporary or lasting remission of disease in spontaneously diabetic NOD mice.
Claims23
An in vitro or ex vivo method for increasing the number of B regulatory (Breg) cells in a population of B cells, the method comprising:
- (i) providing a population of isolated B cells;
- (ii) bringing into contact the population of isolated B cells with an efficient amount of a biocompatible nanoparticle comprising at least one antigen, thereby increasing the number of Breg cells in the population, thereby providing a Breg cells-enriched composition;
- (iii) optionally recovering Breg cells from the Breg cells-enriched composition.
An in vitro or ex vivo method for producing Interleukin-10 (IL-10) or TGF-β, the method comprising:
- (i) providing a population of isolated B cells;
- (ii) bringing into contact the population of isolated B cells with an efficient amount of a biocompatible nanoparticle comprising at least one antigen, thereby producing Interleukin-10 or TGF-β;
- (iii) optionally recovering the Interleukin-10 or TGF-β, from step (ii).
A composition containing a biocompatible nanoparticle comprising at least one antigen;
- in combination with a population of isolated B cells.
A kit comprising:
- a biocompatible nanoparticle comprising at least one antigen;
- and
- a population of isolated B cells.
A method for producing B regulatory (Breg) cells in vivo or for producing Interleukin-10 (IL-10) or TGF-β in vivo, comprising a step of administering a biocompatible nanoparticle comprising at least one antigen.
Dependencies are inferred from the claim text.